Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Weekly channel feed
The past and future of antibodies, as told through HIV; Another big pharma joins CD47 game; and more
4 years ago
Vaccine mandates, biopharma edition; Alzheimer’s ripple effect; Change of guard at J&J; and more
4 years ago
Latest news on Friday afternoon CRL; A big no to Aduhelm; Remembering Tachi with Jim Wilson and Bill Clinton; and more
4 years ago
Biotech grieves over Tachi’s passing; $3 trillion mirage?; Sanofi has a new Pompe drug; and more
4 years ago
Not all mRNA vaccines are created equal. Does it matter?; Neuro is back; Private M&A affair; and more
4 years ago
Novartis reshuffles its wild cards; Tough sell for Biogen? Googling proteins; Ken Frazier's new gig; and more
4 years ago
Biogen pressed against the wall as more stakeholders side against Aduhelm; Prime time for CRISPR 3.0?; and more
4 years ago
Storm brews around Aduhelm as FDA requests probe; Dissecting pipeline disasters; Bob Nelsen is going Really Big; and more
4 years ago
Watch out, Pfizer and Moderna; Anti-aging breakthrough in mice?; Neuro for the new GSK; and more
5 years ago
Are 'platform plays' here to stay?; The Aduhelm saga continues to unfold; A new GSK?; and more
5 years ago
Aduhelm OK 'bittersweet' for ALS advocates; Contrasting Covid-19 vaccine readouts; GSK joins TIGIT battle; and more
5 years ago
Unpacking the Aduhelm decision, Vertex's half full glass, a $525M J&J breakup, and more
5 years ago
What aducanumab means for Alzheimer's, unpacking a safety barrier in CAR-T, the push to upgrade a key ALS trial tool, and more
5 years ago
Latest news: Amgen's landmark OK for KRAS drug, inside Vertex 3.0, the big hunt for CAR-T in solid tumors, and more
5 years ago
Latest news on J&J’s NSCLC approval, Bristol Myers Squibb’s big TIGIT bet, #ASCO21 and more
5 years ago
$DNA is once again on NYSE; FDA clears Soliris challenger for the market; Flagship’s thinking big again with eRNA; and more
5 years ago
Roger Perlmutter’s new gig, Covid-19 IP drama, Vivek Ramaswamy's coach on the SPAC train, and more
5 years ago
Quiet end for flashy upstart, the PD-(L)1 reckoning that wasn't, Big Pharma's Covid-19 year, and more
5 years ago
Latest news: Committee votes to restart J&J vaccinations, checkpoint giants prep defense, underdog vaccine enters the spotlight, and more
5 years ago
Covid-19 vaccine halt drags on, an FDA appointment at long last, the great CRO consolidation, and more
5 years ago
The Endpoints 20 under 40, biotech's new normal, Stéphane Bancel's one regret, and more
5 years ago
Legendary biotech leader passes away, renewed tension around aducanumab, Merck's rare defeat, and more
5 years ago
AstraZeneca's Covid-19 vaccine woes, Moncef Slaoui resigns over sexual harassment claims, FDA acts tough, and more
5 years ago
Merck's C-suite shakeup, Eli Lilly stirs fresh Alzheimer's controvery, play by play of Amgen's $2B buyout, and more
5 years ago
First page
Previous page
6
7
8
9
10
Next page
Last page